Literature DB >> 12021340

Disulfide bond configuration of human cytomegalovirus glycoprotein B.

Matthew Lopper1, Teresa Compton.   

Abstract

Glycoprotein B (gB) is the most highly conserved of the envelope glycoproteins of human herpesviruses. The gB protein of human cytomegalovirus (CMV) serves multiple roles in the life cycle of the virus. To investigate structural properties of gB that give rise to its function, we sought to determine the disulfide bond arrangement of gB. To this end, a recombinant form of gB (gB-S) comprising the entire ectodomain of the glycoprotein (amino acids 1 to 750) was constructed and expressed in insect cells. Proteolytic fragmentation and mass spectrometry were performed using purified gB-S, and the five disulfide bonds that link 10 of the 11 highly conserved cysteine residues of gB were mapped. These bonds are C94-C550, C111-C506, C246-C250, C344-C391, and C573-C610. This configuration closely parallels the disulfide bond configuration of herpes simplex type 2 (HSV-2) gB (N. Norais, D. Tang, S. Kaur, S. H. Chamberlain, F. R. Masiarz, R. L. Burke, and F. Markus, J. Virol. 70:7379-7387, 1996). However, despite the high degree of conservation of cysteine residues between CMV gB and HSV-2 gB, the disulfide bond arrangements of the two homologs are not identical. We detected a disulfide bond between the conserved cysteine residue 246 and the nonconserved cysteine residue 250 of CMV gB. We hypothesize that this disulfide bond stabilizes a tight loop in the amino-terminal fragment of CMV gB that does not exist in HSV-2 gB. We predicted that the cysteine residue not found in a disulfide bond of CMV gB, cysteine residue 185, would play a role in dimerization, but a cysteine substitution mutant in cysteine residue 185 showed no apparent defect in the ability to form dimers. These results indicate that gB oligomerization involves additional interactions other than a single disulfide bond. This work represents the second reported disulfide bond structure for a herpesvirus gB homolog, and the discovery that the two structures are not identical underscores the importance of empirically determining structures even for highly conserved proteins.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12021340      PMCID: PMC136243          DOI: 10.1128/jvi.76.12.6073-6082.2002

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Oligomerization of the human cytomegalovirus major envelope glycoprotein complex gB (gp55-116).

Authors:  W J Britt; L G Vugler
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

2.  Synthesis and processing of the envelope gp55-116 complex of human cytomegalovirus.

Authors:  W J Britt; D Auger
Journal:  J Virol       Date:  1986-04       Impact factor: 5.103

3.  The nucleotide sequence of the gB glycoprotein gene of HSV-2 and comparison with the corresponding gene of HSV-1.

Authors:  D J Bzik; C Debroy; B A Fox; N E Pederson; S Person
Journal:  Virology       Date:  1986-12       Impact factor: 3.616

4.  Altered cellular mRNA levels in human cytomegalovirus-infected fibroblasts: viral block to the accumulation of antiviral mRNAs.

Authors:  E P Browne; B Wing; D Coleman; T Shenk
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Functional analysis of the disulfide-bonded loop/chain reversal region of human immunodeficiency virus type 1 gp41 reveals a critical role in gp120-gp41 association.

Authors:  A L Maerz; H E Drummer; K A Wilson; P Poumbourios
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

6.  Transformation of rat cells by DNA of human adenovirus 5.

Authors:  F L Graham; A J van der Eb
Journal:  Virology       Date:  1973-08       Impact factor: 3.616

7.  Global modulation of cellular transcription by human cytomegalovirus is initiated by viral glycoprotein B.

Authors:  K A Simmen; J Singh; B G Luukkonen; M Lopper; A Bittner; N E Miller; M R Jackson; T Compton; K Früh
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

8.  Human cytomegalovirus penetrates host cells by pH-independent fusion at the cell surface.

Authors:  T Compton; R R Nepomuceno; D M Nowlin
Journal:  Virology       Date:  1992-11       Impact factor: 3.616

9.  Neutralizing antibodies detect a disulfide-linked glycoprotein complex within the envelope of human cytomegalovirus.

Authors:  W J Britt
Journal:  Virology       Date:  1984-06       Impact factor: 3.616

10.  Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.

Authors:  M P Cranage; T Kouzarides; A T Bankier; S Satchwell; K Weston; P Tomlinson; B Barrell; H Hart; S E Bell; A C Minson
Journal:  EMBO J       Date:  1986-11       Impact factor: 11.598

View more
  14 in total

1.  Herpes simplex virus glycoprotein B binds to cell surfaces independently of heparan sulfate and blocks virus entry.

Authors:  Florent C Bender; J Charles Whitbeck; Huan Lou; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

2.  Sustained expression of human cytomegalovirus glycoprotein B (UL55) in the seeds of homozygous rice plants.

Authors:  Eilleen S Tackaberry; Fiona A Prior; Karen Rowlandson; Monika Tocchi; Jelica Mehic; Suzanne Porter; Mike Walsh; Mark R Schleiss; Peter R Ganz; Ravinder K Sardana; Illimar Altosaar; Anil K Dudani
Journal:  Mol Biotechnol       Date:  2008-04-16       Impact factor: 2.695

3.  Antigenic domain 1 is required for oligomerization of human cytomegalovirus glycoprotein B.

Authors:  William J Britt; Michael A Jarvis; Derek D Drummond; Michael Mach
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

4.  Human cytomegalovirus elicits a coordinated cellular antiviral response via envelope glycoprotein B.

Authors:  Karl W Boehme; Jasbir Singh; Stuart T Perry; Teresa Compton
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Specific inhibition of human cytomegalovirus glycoprotein B-mediated fusion by a novel thiourea small molecule.

Authors:  Thomas R Jones; Shi-Wu Lee; Stephen V Johann; Vladimir Razinkov; Robert J Visalli; Boris Feld; Jonathan D Bloom; John O'Connell
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

6.  Novel trimeric human cytomegalovirus glycoprotein B elicits a high-titer neutralizing antibody response.

Authors:  Xinle Cui; Zhouhong Cao; Shuishu Wang; Ronzo B Lee; Xiao Wang; Haruhiko Murata; Stuart P Adler; Michael A McVoy; Clifford M Snapper
Journal:  Vaccine       Date:  2018-08-03       Impact factor: 3.641

7.  Recombinant modified vaccinia virus Ankara expressing a soluble form of glycoprotein B causes durable immunity and neutralizing antibodies against multiple strains of human cytomegalovirus.

Authors:  Zhongde Wang; Corinna La Rosa; Rebecca Maas; Heang Ly; John Brewer; Shahram Mekhoubad; Pirouz Daftarian; Jeff Longmate; William J Britt; Don J Diamond
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

8.  Expression and characterization of a soluble form of tomato spotted wilt virus glycoprotein GN.

Authors:  Anna E Whitfield; Diane E Ullman; Thomas L German
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

9.  Peptide inhibition of human cytomegalovirus infection.

Authors:  Lilia I Melnik; Robert F Garry; Cindy A Morris
Journal:  Virol J       Date:  2011-02-22       Impact factor: 4.099

10.  B cell repertoire analysis identifies new antigenic domains on glycoprotein B of human cytomegalovirus which are target of neutralizing antibodies.

Authors:  Sonja Pötzsch; Nadja Spindler; Anna-Katharina Wiegers; Tanja Fisch; Pia Rücker; Heinrich Sticht; Nina Grieb; Tina Baroti; Florian Weisel; Thomas Stamminger; Luis Martin-Parras; Michael Mach; Thomas H Winkler
Journal:  PLoS Pathog       Date:  2011-08-11       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.